Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. Equillium, Inc. has a research collaboration agreement with Vivtex Corporation to develop GI-targeted formulations for Bi-specific peptide therapy. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

Period	PE Ratio
2018-12-31	N/A
2019-12-31	N/A
2020-12-31	-2.09
2021-12-31	-2.24
2022-12-31	-1.65
2023-12-31	-8.03
2024-12-31	-13.26
2025-12-31	-7.82

	A	B	C	D
1	Symbol	Price	Change	Volume
2	EQ	$3.05	+2.01%	0.42M
3
4
5

Equillium Inc. (EQ) PE Ratio

PE Ratio Data

Get Equillium Inc. Data in Excel

More EQ Financial Data